Market Overview

Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Related RGEN
2 Biotech Stocks That Crushed On Earnings
Repligen (RGEN) Shares March Higher, Can It Continue? - Tale of the Tape
Related PFE
Earnings Expectations For The Week Of July 28: Exxon, Pfizer, Twitter And Much More
Benzinga Weekly Preview: FOMC In Focus, As Earnings Season Progresses
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

Repligen Corporation (NASDAQ: RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Posted-In: News FDA

 

Most Popular

Related Articles (RGEN + PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters